• SenesTech, with its proprietary biological solution for efficiently and safely reducing rat populations without killing, represents a remarkable new path to clean cities, businesses, and households
• According to pest industry figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States
• ContraPest offers a unique solution for wastewater facilities because it is non-poisonous and comes in a variety of formats that can help control rat populations where other approaches fall short

SenesTech (NASDAQ: SNES), the rodent fertility control experts and the inventor of the only EPA-registered contraceptive for male and female rats, recently announced that its ContraPest(R) is being deployed in Washington and California through wastewater treatment facilities. Controlling rat infestations presents a unique challenge for wastewater treatment facilities because poisons cannot be introduced into the water supply, and ground-based stations may not be appropriate for many of the facilities.

“Municipalities and government entities comprise a broad and diverse customer base. We are continuously working with these customers, and the pest management professionals who service them, to understand their specific needs and to guide them as to how best to add ContraPest to their integrated pest management system,” said Joel Fruendt, President and CEO of SenesTech (https://ibn.fm/OxgPz). “Wastewater treatment deployment has very specific challenges, and we are able to develop and share deployment protocols utilized by other, similar customers.”

SenesTech strives for clean cities, efficient businesses, and happy households with a product scientifically designed to be effective without killing rats. The company’s first product, ContraPest, applies revolutionary technology to a challenge that has plagued the world since the Middle Ages – the increase of rat populations in urban and agricultural settings. The ContraPest formulation is a highly palatable liquid promoting sustained consumption. It targets the reproductive capabilities of Norway and roof rats, reducing fertility in both male and female rats, bringing populations down, and keeping them down.

SenesTech’s flagship offering, ContraPest, can be used as part of an integrated pest management (“IPM”) program – fitting seamlessly into all IPM programs, reducing reproduction, and magnifying the success of these protocols. It can also be used as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods. ContraPest reduced rat activity by up to 95% in multiple independent field deployments when added to an existing IPM program.

The global rodenticides market is expected to reach a revenue of $7.1 billion by 2027, growing at a CAGR of 5.8%. The market’s growth is attributed to the rising concern for environmental pollution and public health hazards posed by vector-borne diseases, fueling the global demand for rodent control services. The growing population, limited resources, and ecosystem degradation are factors that contribute to the rodents’ ability to survive in different seasons and overpopulation (https://ibn.fm/KrIW0).

Rats are known to spread at least 35 diseases, posing a dangerous risk to public health and safety across the globe. This problem persists despite extensive campaigns to eradicate it, and multiple sources have reported a boom in post-COVID rat populations. Although poison-based control methods sicken rats, they die slowly – and when an animal eats these infected rats, it can also make that animal sick.

ContraPest is available in three unique bait systems – the Ultimate Bait System(TM), Elevate Bait System(TM), and Isolate Bait system(TM). The active ingredients in ContraPest are specifically formulated for rats and break down in their digestive system, resulting in no bioaccumulation or biomagnification in the environment.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN